Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:01:29.420Z.
Calculation as of: 2026-10-06T19:01:29.420Z.
Quote observation: 2026-10-06T18:59:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fb444e1e26cbd5896b6e324764cb09ba059118d447e0aa37aaedcb3e28ce7b2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$6.58M
EBITDA Yield
N/A
TTM Avg
3.10%
3Y Avg
3.10%
5Y Avg
1.95%
Market Cap
$6.94M
EBITDA Yield
N/A
TTM Avg
372.43%
3Y Avg
151.61%
5Y Avg
151.61%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.60M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 3.10% | 3.10% | 1.95% |
| Aclarion, Inc. (ACON)vs › | $6.62M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.54M | N/A | 1.29% | 1.35% | 1.32% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.78M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $7.01M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.22M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | N/A | 372.43% | 151.61% | 151.61% |
| KALA BIO, Inc. (KALA)vs › | $6.91M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.04M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
